Literature DB >> 5676521

Red cell life span after splenectomy in hereditary spherocytosis.

R G Chapman, L L McDonald.   

Abstract

Despite the persistence of spherocytosis after splenectomy in hereditary spherocytosis, it has usually been assumed that red cell life span returns completely to normal after this treatment. Diisopropyl fluorophosphate. DF(32)P, a noneluting red cell label, was given intravenously to 11 patients in five unrelated families 2-27 yr after splenectomy for typical hereditary spherocytosis. Hemoglobin ranged from 14.0 to 19.8 g/100 ml in this group and reticulocytes from 1.1 to 2.9%, showing the excellent clinical response to splenectomy. Loss of red cell radioactivity corrected for radiophosphorus decay was linear with time during the 60-70 days of the study. Red cell survival as indicated by this rate of loss was 96 +/- 13 days (range 76-118 days), significantly less than the 123 +/- 14 days observed with the same method in 12 persons with normal red cells (P < 0.0005). I conclude that splenectomy does not eliminate the decreased red cell survival in hereditary spherocytosis. The residual 22% decrease in red cell survival is clinically unimportant, but it must be considered in evaluation of biochemical differences observed in hereditary spherocytic red cells.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 5676521      PMCID: PMC297390          DOI: 10.1172/JCI105911

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  11 in total

1.  ERYTHROCYTE LIPIDS: A COMPARISON OF NORMAL YOUNG AND NORMAL OLD POPULATIONS.

Authors:  M P WESTERMAN; L E PIERCE; W N JENSEN
Journal:  J Lab Clin Med       Date:  1963-09

2.  Hyposplenism: an inquiry into normal functions of the spleen.

Authors:  W H CROSBY
Journal:  Annu Rev Med       Date:  1963       Impact factor: 13.739

3.  Analysis of red-cell survival curves in clinical practice and the use of di-iso-propylfluorophosphonate (DF32P) as a label for red cells in man.

Authors:  L GARBY
Journal:  Br J Haematol       Date:  1962-01       Impact factor: 6.998

4.  Erythrocyte survival-time determinations with the aid of DF32P.

Authors:  J G EERNISSE; J van ROOD
Journal:  Br J Haematol       Date:  1961-07       Impact factor: 6.998

5.  Studies on the mechanism of aging of human red blood cells.

Authors:  P A MARKS; A B JOHNSON; E HIRSCHBERG; J BANKS
Journal:  Ann N Y Acad Sci       Date:  1958-10-13       Impact factor: 5.691

6.  Leukokinetic studies. I. A method for labeling leukocytes with diisopropyl-fluorophosphate (DFP32).

Authors:  J W ATHENS; A M MAUER; H ASHENBRUCKER; G E CARTWRIGHT; M M WINTROBE
Journal:  Blood       Date:  1959-04       Impact factor: 22.113

7.  Effect of spherocytosis on volume of trapped plasma in red cell column of capillary and Wintrobe hematocrits.

Authors:  F W FURTH
Journal:  J Lab Clin Med       Date:  1956-09

8.  The use of radioactive sodium chromate to evaluate the life span of the red blood cell in health and certain hematologic disorders.

Authors:  R C READ; G W WILSON; F H GARDNER
Journal:  Am J Med Sci       Date:  1954-07       Impact factor: 2.378

9.  The interpretation of red cell survival curves.

Authors:  A C DORNHORST
Journal:  Blood       Date:  1951-12       Impact factor: 22.113

10.  Glycolysis and glycolytic enzyme activity of aging red cells in man. Changes in hexokinase, aldolase, glyceraldehyde-3-phosphate dehydrogenase, pyruvate kinase and glutamic-oxalacetic transaminase.

Authors:  R G Chapman; L Schaumburg
Journal:  Br J Haematol       Date:  1967-09       Impact factor: 6.998

View more
  10 in total

1.  Localization of spherocytosis to chromosome 8 or 12 and report of a family with spherocytosis and a reciprocal translocation.

Authors:  W J Kimberling; T Fulbeck; L Dixon; H A Lubs
Journal:  Am J Hum Genet       Date:  1975-09       Impact factor: 11.025

2.  The Gardos effect drives erythrocyte senescence and leads to Lu/BCAM and CD44 adhesion molecule activation.

Authors:  Thomas R L Klei; Jill J Dalimot; Boukje M Beuger; Martijn Veldthuis; Fatima Ait Ichou; Paul J J H Verkuijlen; Iris M Seignette; Peter C Ligthart; Taco W Kuijpers; Rob van Zwieten; Robin van Bruggen
Journal:  Blood Adv       Date:  2020-12-22

3.  Post-splenectomy megathrombocythaemia hypothesis: absence of splenic storage.

Authors:  B Harding; J O'Grady; F Given; C McCarthy; B Murphy; E Egan
Journal:  Ir J Med Sci       Date:  1987-06       Impact factor: 1.568

Review 4.  Hereditary spherocytosis revisited. Eighth annual Paul M. Aggeler Memorial Lecture. Delivered October 25, 1977, San Francisco General Hospital Medical Center.

Authors:  W N Valentine
Journal:  West J Med       Date:  1978-01

5.  Folic acid deficiency in congestive heart failure.

Authors:  J I Brody; H D Soltys; H F Zinsser
Journal:  Br Heart J       Date:  1969-11

6.  A laparoscopic approach to partial splenectomy for children with hereditary spherocytosis.

Authors:  S Dutta; V E Price; V Blanchette; J C Langer
Journal:  Surg Endosc       Date:  2006-10-05       Impact factor: 4.584

7.  Hereditary spherocytosis: evaluation of 68 children.

Authors:  Çapan Konca; Murat Söker; Mehmet Ali Taş; Ruken Yıldırım
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

8.  Red cell survival studies in hereditary spherocytosis.

Authors:  J S Wiley
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

9.  The role of membrane lipids in the survival of red cells in hereditary spherocytosis.

Authors:  R A Cooper; J H Jandl
Journal:  J Clin Invest       Date:  1969-04       Impact factor: 14.808

10.  Vasculo-toxic and pro-inflammatory action of unbound haemoglobin, haem and iron in transfusion-dependent patients with haemolytic anaemias.

Authors:  Francesca Vinchi; Richard Sparla; Sara T Passos; Richa Sharma; S Zebulon Vance; Hala S Zreid; Hesham Juaidi; Deepa Manwani; Karina Yazdanbakhsh; Vijay Nandi; André M N Silva; Anand R Agarvas; Eitan Fibach; John D Belcher; Gregory M Vercellotti; Husam Ghoti; Martina U Muckenthaler
Journal:  Br J Haematol       Date:  2021-03-15       Impact factor: 6.998

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.